Trial · NCT05925140
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
NCT05925140, Phase 1, Unknown, Lebanese University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients. Trials, record NCT05925140. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05925140
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
- NCT number
- NCT05925140
- Status
- Unknown
- Phases
- Phase 1
- Enrollment
- 1,000 participants, estimated
- Lead sponsor
- Lebanese University
- Conditions
- COVID-19, Hospitalized COVID-19 Patients
- Interventions
- Lopinavir / Ritonavir, Remdesivir (RDV), Tocilizumab, Corticosteroid Therapy-enhanced Standard Care (CTSC)
- First posted
- 2023-06-29
- Last updated
- 2024-02-06
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality rate | 28-day mortality rate | The number of deaths recorded in each arm over a specified period |
| Primary | Clinical improvement rate | 28-day mortality rate | The proportion of patients showing improvement in clinical symptoms and overall health status in each arm |
| Secondary | Time to clinical recovery | 28-day period | The duration taken for patients to achieve clinical recovery, such as resolution of fever, improvement in respiratory symptoms, and normalization of laboratory markers within 28-day period. |
| Secondary | Length of hospital stay | 28-day period | The number of days patients spend in the hospital from admission to discharge or until a predefined endpoint within a 28-day period. |
| Secondary | Disease progression rate | 28-day period | The rate at which patients experience disease progression, such as the development of severe respiratory distress or organ failure, within a 28-day period. |
| Secondary | Adverse events | 28-day period | The occurrence of any adverse events or side effects related to the treatments in each arm, including drug-related complications or complications associated with immunosuppression, within a 28-day period. |
| Secondary | Viral clearance rate | 28-day period | The rate at which patients in each treatment arm achieve clearance of the SARS-CoV-2 virus from respiratory samples, indicating a reduction in viral replication, within a 28-day period. |
| Secondary | Biomarker changes | 28-day period | Evaluation of changes in specific biomarkers associated with disease severity, inflammation, immune response, or organ dysfunction in each treatment arm within a 28-day period. |
| Secondary | Questionnaire about the quality of life | 28-day period | Assessment of patients' quality of life measures, including physical functioning, psychological well-being, and social aspects, using standardized questionnaires within a 28-day period. |
| Secondary | Healthcare resource utilization | 28-day period | Examination of the utilization of healthcare resources, such as the need for intensive care, mechanical ventilation, or other supportive interventions, in each treatment arm within a 28-day period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05925140
GET https://conductscience.org/api/trials/v1/NCT05925140/registered